Ipsen’s Acquisition of Epizyme

Orrick Herrington & Sutcliffe advised Ipsen on the deal. Global biopharmaceutical company Ipsen (Euronext: IPN; ADR: IPSEY) announced its definitive agreement to acquire Epizyme (Nasdaq: EPZM), a...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here